1.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(AMENDMENT 1)
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended October 2, 1994
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from________to_______
COMMISSION FILE NUMBER 1-3619
--
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE 13-5315170
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices, including zip code)
(212) 573-2323
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that
registrant was required to file such reports) and (2) has been subject to
such filing requirements for the past 90 days.
YES X NO
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
At October 31, 1994, there were 314,778,431 shares, par value $.10, of the
issuer's common stock outstanding.
Reason for Filing Form 10-Q (Amendment 1)
Form 10-Q Amendment 1 is being filed for the third quarter of 1994 for
Pfizer Inc. because when Form 10-Q was filed on November 15, 1994,
Exhibit 27 was not submitted in the proper format.
<PAGE>
2.
Item 6: Exhibits and Reports on Form 8-K
(a) Exhibits
1) Exhibit 11 - Computation of Earnings Per Common Share
(previously filed 11/15/94)
2) Exhibit 12 - Computation of Ratio of Earnings to Fixed Charges
(previously filed 11/15/94)
3) Exhibit 15 - Accountants' Acknowledgement
(previously filed 11/15/94)
4) Exhibit 27 - Financial Data Schedule
(b) No reports on Form 8-K have been filed by the Company during the
third quarter ended October 2, 1994.
<PAGE>
3.
PFIZER INC. AND SUBSIDIARY COMPANIES
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereto duly authorized.
Pfizer Inc.
(Registrant)
Date: December 21, 1994
H. V. Ryan; Controller
(Principal Accounting Officer and
Duly Authorized Officer)
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>THIS SCHEDULE CONTAINS SUMMARY FINANCIAL
INFORMATION EXTRACTED FROM PFIZER INC. AND SUBSIDIARY
COMPANIES CONDENSED CONSOLIDATED BALANCE SHEET AND
CONDENSED STATEMENT OF INCOME FOR THE PERIOD ENDED
OCTOBER 2, 1994 AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
<MULTIPLIER> 1,000,000
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-1994
<PERIOD-END> OCT-2-1994
<CASH> 894
<SECURITIES> 517
<RECEIVABLES> 1,684
<ALLOWANCES> (42)
<INVENTORY> 1,268
<CURRENT-ASSETS> 5,426
<PP&E> 4,841
<DEPRECIATION> (1,899)
<TOTAL-ASSETS> 10,402
<CURRENT-LIABILITIES> 4,139
<BONDS> 586
<COMMON> 34
0
0
<OTHER-SE> 4,120
<TOTAL-LIABILITY-AND-EQUITY> 10,402
<SALES> 5,981
<TOTAL-REVENUES> 5,981
<CGS> 1,372
<TOTAL-COSTS> 1,372
<OTHER-EXPENSES> 3,139
<LOSS-PROVISION> 10
<INTEREST-EXPENSE> 96
<INCOME-PRETAX> 1,383
<INCOME-TAX> 415
<INCOME-CONTINUING> 964
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 964
<EPS-PRIMARY> 3.11
<EPS-DILUTED> 3.11
</TABLE>
